These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12578850)

  • 1. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression.
    Zinger H; Eilat E; Meshorer A; Mozes E
    Int Immunol; 2003 Feb; 15(2):205-14. PubMed ID: 12578850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
    Luger D; Dayan M; Zinger H; Liu JP; Mozes E
    J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus.
    Faber-Elmann A; Eilat E; Zinger H; Mozes E
    Clin Immunol; 2002 Nov; 105(2):223-32. PubMed ID: 12482397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody.
    Eilat E; Zinger H; Nyska A; Mozes E
    J Clin Immunol; 2000 Jul; 20(4):268-78. PubMed ID: 10939714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.
    Eilat E; Dayan M; Zinger H; Mozes E
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1148-53. PubMed ID: 11158609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peptide derived from an autoantibody can stimulate T cells in the (NZB x NZW)F1 mouse model of systemic lupus erythematosus.
    Ebling FM; Tsao BP; Singh RR; Sercarz E; Hahn BH
    Arthritis Rheum; 1993 Mar; 36(3):355-64. PubMed ID: 7680861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
    Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
    Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A; Azulai H; Sthoeger ZM; Mozes E
    Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.
    Waisman A; Ruiz PJ; Israeli E; Eilat E; Könen-Waisman S; Zinger H; Dayan M; Mozes E
    Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4620-5. PubMed ID: 9114040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.
    Brosh N; Eilat E; Zinger H; Mozes E
    Immunology; 2000 Feb; 99(2):257-65. PubMed ID: 10692045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
    Mauermann N; Sthoeger Z; Zinger H; Mozes E
    Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
    Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
    J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
    Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
    Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBXNZW)F1 lupus-prone mice.
    Brosh N; Dayan M; Fridkin M; Mozes E
    Immunol Lett; 2000 Apr; 72(1):61-8. PubMed ID: 10789683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus.
    McMurray RW; Elbourne KB; Lagoo A; Lal S
    J Rheumatol; 1998 Dec; 25(12):2364-70. PubMed ID: 9858431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.
    Sthoeger ZM; Zinger H; Mozes E
    Ann Rheum Dis; 2003 Apr; 62(4):341-6. PubMed ID: 12634234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.
    Sthoeger ZM; Dayan M; Tcherniack A; Green L; Toledo S; Segal R; Elkayam O; Mozes E
    Clin Exp Immunol; 2003 Feb; 131(2):385-92. PubMed ID: 12562403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner.
    Liu Z; Bethunaickan R; Huang W; Lodhi U; Solano I; Madaio MP; Davidson A
    Arthritis Rheum; 2011 Jan; 63(1):219-29. PubMed ID: 20954185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.